Autism Clinical Trial
Official title:
Cholesterol in Autism Spectrum Disorder (ASD): Characterization and Treatment
Verified date | June 8, 2015 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background:
- Autism spectrum disorders (ASD) are developmental disabilities characterized by impaired
social interaction and repetitive and/or stereotypical behaviors. Research studies suggest
that some individuals with ASD have very low blood cholesterol levels. This low cholesterol
level and other abnormal sterol levels may be important markers for
subtypes of ASD. Providing additional cholesterol to the diets of children with ASD may help
improve behavior.
- These findings will guide the medical community in identifying individuals who should be
tested for sterol disorders. This study will also help researchers learn whether adding extra
cholesterol to the diet will improve behavioral and other autism spectrum characteristics
seen in individuals with ASD and low cholesterol.
Objectives:
- To determine cholesterol levels in children with autism spectrum disorders.
- To compare behavioral and other characteristics among children who have autism spectrum
disorders and high, low, or normal cholesterol levels.
- To determine whether adding cholesterol to the diet will improve behavioral and other
characteristics in individuals with ASD and low cholesterol.
Eligibility:
- Children between the ages of 4 and 12 who have been diagnosed with an autism spectrum
disorder.
Design:
- Initial screening study will involve a collection of blood samples (for study purposes
and cholesterol testing).
- Children who have low cholesterol levels will take part in a study in which they will
receive either cholesterol supplementation or a placebo, and will have detailed physical
and psychological examinations to measure possible improvement in behavioral or other
characteristics.
- Children who have high or normal cholesterol levels will have further blood samples
taken, and will undergo an additional set of examinations for comparison purposes.
- Researchers may request blood or DNA samples from other family members (parents or
siblings), which will be collected through blood draws and cheek swabs.
Status | Completed |
Enrollment | 44 |
Est. completion date | November 14, 2013 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 4 Years to 12 Years |
Eligibility |
- INCLUSION/EXCLUSION CRITERIA: Screening Visit: Inclusion: - Parents agree to use a multivitamin with minerals if their child is selected to continue to the cholesterol supplementation clinical trial. - Parents agree to not change the doses of other dietary supplement throughout the clinical trial, including megavitamins. - Supplements or medications that are not meant to lower cholesterol levels but are likely to have cholesterol-lowering effects (such as Omega 3 or fish oil) will be permitted if the dose has been stable for at least 3 months prior to the initial screening visit. - Male or female between the ages of 4.0-12.0 years at the time of consent/assent. - Clinically diagnosed with an ASD for which no cause has been detected. - Anticonvulsants used for the treatment of a seizure disorder will be permitted if the dosage has been stable for 3 months, and the subject is seizure free for at least 3 months. Exclusion: - Known pregnancy. - Subject has SLOS or known cholesterol synthesis/regulation disorder. - The subject has had an anticonvulsant dose change in the preceding 3 months or a seizure in the preceding 3 months. - DSM-IV diagnosis of Rett Disorder, childhood disintegrative disorder, schizophrenia, another psychotic disorder, or substance abuse. - A significant medical condition such as heart disease, hypertension, liver or renal failure, pulmonary disease, diabetes, or unstable seizure disorder identified by history, physical examination, or laboratory tests. - Dietary supplementation doses, including megavitamins, have changed within the preceding 3 months. - Currently on or has taken a statin or other medication meant to lower cholesterol within the preceding 3 months. - Currently on or has taken dietary cholesterol supplementation within the preceding 3 months. - Subjects will be excluded if they are on other medications or supplements that affect cholesterol or other lipid levels. - Subjects with gastronomy feeding tubes (G-tubes) will be excluded. - Subjects for whom English is not the primary language will be excluded. (No subjects will be excluded based on race, ethnicity or gender). Characterization Visit: Inclusion: - Same inclusion criteria as the Screening Visit. - Participants must have a mental age of 18 months as measured at the Characterization Visit by the age-appropriate form of the Stanford Binet-V, the Differential Abilities Scale, or the Mullen Scales of Early Learning (N.B. potential subjects who test below 18 months of age, but are otherwise eligible, may be admitted to the study following a case review convened by the Multisite Steering Committee). - Child must have an ASD diagnosis using DSM-IV and clinical judgment in order to proceed to the other components of the Characterization Visit. - Neuroleptics will be permitted for the ASD+Hypo group only if the dosage remains stable for the duration of the study. - Neuroleptic medication free for at least three months (ASD+Hyper and ASD+Normal only). Exclusion: - Same exclusion criteria as the Screening Visit. - Allergy to lanolin or soy (Hypo+ASD only). - Non-verbal mental age below 18 months as measured by the developmentally-appropriate form of the Stanford-Binet-V, Differential Abilities Scale, or the Mullen Scales of Early Learning (N.B. potential subjects who test below 18 months of age, but are otherwise eligible, may be admitted to the study following a case review convened by the Multisite Steering Committee). - Did not meet the criteria for an ASD during the Characterization Visit. Double-Blind, Placebo-Controlled trial phase for ASD+Hypo Only: Inclusion: - Met Characterization Visit inclusion criteria and completed Characterization Visit procedures. - Met criteria for hypocholesterolemia in ASD. Exclusion: -Same exclusion criteria as the Characterization Visit. Open-Label Trial for ASD+Hypo only: Inclusion: - Subject continues to meet double-blind, placebo-controlled trial phase inclusion criteria. Exclusion: - Subject started a neuroleptic medication or medication that affects cholesterol synthesis or metabolism. Family Members of ASD+Hypo only: Inclusion: - Biological parent(s) and full or half-sibling(s) of any age. Exclusion: - Those individuals not willing to provide a blood sample or a saliva sample for DNA. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
United States,
Elias ER, Irons MB, Hurley AD, Tint GS, Salen G. Clinical effects of cholesterol supplementation in six patients with the Smith-Lemli-Opitz syndrome (SLOS). Am J Med Genet. 1997 Jan 31;68(3):305-10. — View Citation
Irons M, Elias ER, Abuelo D, Bull MJ, Greene CL, Johnson VP, Keppen L, Schanen C, Tint GS, Salen G. Treatment of Smith-Lemli-Opitz syndrome: results of a multicenter trial. Am J Med Genet. 1997 Jan 31;68(3):311-4. — View Citation
Kaufmann WE, Cortell R, Kau AS, Bukelis I, Tierney E, Gray RM, Cox C, Capone GT, Stanard P. Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am J Med Genet A. 2004 Sep 1;129A(3):225-34. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Behavioral Changes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05302167 -
Molehill Mountain Feasibility Study.
|
N/A | |
Completed |
NCT04167839 -
Effects of Sensory Diets on Children's Sensory Processing Skills, Psychosocial Skills, and Classroom Engagement
|
N/A | |
Terminated |
NCT04049981 -
Investigation of Mechanisms of Action in Superpower Glass
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06080087 -
Implementation Toolkit to Enhance EBP Among Marginalized Families
|
N/A | |
Recruiting |
NCT04107064 -
Achieving Steady Work Among Adults With Autism Through Specialized Employment Program
|
N/A | |
Completed |
NCT03206996 -
Exposure Therapy for Auditory Sensitivity in Autism
|
N/A | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Completed |
NCT05588570 -
Coaching Children With Anxiety and Autism Through Telehealth
|
N/A | |
Enrolling by invitation |
NCT06058104 -
Evaluating Efficacy of a Digital Game Therapeutic for Children With Autism
|
N/A | |
Withdrawn |
NCT02414451 -
Trial of Propranolol in Adults and Adolescents With ASD and Predictors of Response
|
N/A | |
Completed |
NCT02911194 -
a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD)
|
N/A | |
Completed |
NCT03002363 -
The Effects of Video Modeling of Audiological Testing on Pediatric Patient Compliance
|
Phase 1 | |
Completed |
NCT02847182 -
Cord Blood Infusion for Children With Autism Spectrum Disorder
|
Phase 2 | |
Completed |
NCT02708290 -
Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With ASD
|
||
Completed |
NCT02720900 -
Prebiotic Intervention for Autism Spectrum Disorders
|
N/A | |
Completed |
NCT02536365 -
Sensory Integration Therapy in Autism: Mechanisms and Effectiveness
|
N/A | |
Completed |
NCT02508922 -
Trial of Vitamin D3 Supplementation in Paediatric Autism
|
N/A | |
Recruiting |
NCT02255565 -
Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
|
Phase 4 | |
Recruiting |
NCT01836562 -
A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Autism
|
Phase 1/Phase 2 | |
Completed |
NCT02154828 -
Clinical Evaluation of Integrative Practices Units Infant and Child Care for Unit Children With Typical or Atypical Autism (AUTISM)
|